Emerging treatments for irritable bowel syndrome

REFERENCES

• DROSSMAN DA, CORAZZIARI E, TALLEY NJ etal.: Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut (1999) 45:1-81. ••Rome II criteria for diagnosing IBS.
   Google Scholar
• CAMILLERI M, WILLIAMS DE: Economic burden of irritable bowel syndrome reappraised with strategies to control expenditures. Pharmacoeconomics (2000) 4:331–338.
   Google Scholar
• MANNING AP THOMPSON WG, HEATON KW et al: Towards a positive diagnosis of the irritable bowel. Br Med. (1978) 2:653-654. •Manning criteria: the first major set of criteria for diagnosing IBS.
   Google Scholar
• DE PONTI F, TONINI M: Irritable bowel syndrome. New agents targeting serotonin receptor subtypes. Drugs (2001) 61(3):317–332. ••Comprehensive, well-written review of 5-HT-mediated agents in IBS.
   Google Scholar
• GERSHON MD: Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharmacol Ther. (1999) 13:15–30.
   PubMed Web of Science ®Google Scholar
• GALLIGAN JJ, SURPRENANT A, TONINI M etal.: Differential localization of 5-HT1receptors on myenteric and submucosal neurones. Am. J Physiol (1988) 255:G603–G611.
   Google Scholar
• DIETRICH C, KILBINGER H: 5-HT1A receptor mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms. Neuropharmacology (1996) 35:483–488.
   Google Scholar
• BORMAN RA, BURLEIGH DE: Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. Br. j Pharmacol (1993) 110:927–928.
   PubMed Web of Science ®Google Scholar
• STEIN C: The control of pain in peripheraltissue by opioids. N Engl. j Med. (1995) 332:1685–1690.
   PubMed Web of Science ®Google Scholar
• KUMAR D, WINGATE DL: The irritable bowel syndrome: a paroxysmal motor disorder. Lancet (1985) 2:973–977.
   PubMed Web of Science ®Google Scholar
• KELLOW JE, PHILLIPS SF: Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology (1987) 92:1885–1893.
   PubMed Web of Science ®Google Scholar
• DROSSMAN DA, WHITEHEAD WE, CAMILLERI M: Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology (1997) 112:2120-2137. ••The most recent AGA recommendationsprepared by major figures in IBS research. Very comprehensive.
   Google Scholar
• WHITEHEAD WE, ENGEL BT, SCHUSTER MM: Irritable bowel syndrome: physiological and psychological differences between diarrhoea-predominant and constipation-predominant patterns. Dis. Sci. (1980) 29:1236–1243.
   Google Scholar
• COOK IJ, VAN EEDEN A, COLLINS SM: Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology (1987) 93:727–733.
   PubMed Web of Science ®Google Scholar
• DROSSMAN DA: Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am. j Med. (1999) 107:41S–50S.
   Google Scholar
• NEAL KR, HEBDEN J, SPILLER R: Prevalence of gastrointestinal symptoms six months after bacterial gastro-enteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br Med. J. (1997) 314:779–782.
   PubMed Web of Science ®Google Scholar
• COLLINS SM, VALLANCE B, BARBARA G, BORGAONKAR M: Putative inflammatory and immunological mechanisms in functional bowel disorders. Bai1liereClin. Castro. (1999) 13:429–436.
   Google Scholar
• GWEE KA, GRAHAM JC, MCKENDRICK MW et al: Psychological scores and persistence of irritable bowel after infectious diarrhoea. Lancet (1996) 347:150–153.
   PubMed Web of Science ®Google Scholar
• COLLINS SM: Stress and the gastrointestinal tract. IV. Modulation of intestinal inflammation by stress: basic mechanisms and clinical relevance. Am. Physiol Gastrointest. Liver Physiol. (2001) 280:G315–G318.
   Google Scholar
• BEARCROFT CP, PERRET D, FARTHIING MJG: Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut (1998) 42:42–6.
   PubMed Web of Science ®Google Scholar
• BOSE M, NICKOLS C, FEAKINS R et al: 5-hydroxytryptamine and enterochromaffln cells in the irritable bowel syndrome. Gastroenterology (2000) 118:A563.
   Google Scholar
• MAYER EA: Emerging disease model for functional gastrointestinal disorders. Am. Med. (1999) 107:12S–19S.
   Google Scholar
• MALAGELADA JR: Review article: clinicalpharmacology models of irritable bowel syndrome. Aliment. Pharmacol Ther (1999) 13:57–64.
   Google Scholar
• DROSSMAN DA: Review article: an integrated approach to the irritable bowel syndrome. Aliment. Pharmacol Ther. (1999) 13:3–14.
   PubMedGoogle Scholar
• CAMILLERI M: Management of the irritable bowel syndrome. Gastroenterology (2001) 120:652–668.
   PubMed Web of Science ®Google Scholar
• HORWITZ BJ, FISHER RS: The irritable bowel syndrome. N Engl. I Med. (2001) 344:1846–1850.
   PubMed Web of Science ®Google Scholar
• KLEIN KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology (1988) 95:232-241. •Early review of trials in IBS which highlighted a deficiency of and need for rigorous studies.
   Google Scholar
• AKEHURST R, KALTENTHALER E: Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut (2001) 48:272–282.
   PubMed Web of Science ®Google Scholar
• JAILWALA J, IMPERIALE TF, KROENKE K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomised, controlled trials. Ann. Intern. Med. (2000) 133: 136–147. •A more recent review of RCTs of pharmacological treatment in IBS.
   Google Scholar
• POYNARD T, REGIMBEAU C, BENHAMOU Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol Ther. (2001) 15:355–361.
   PubMed Web of Science ®Google Scholar
• JACKSON HL, O'MALLEY PG, TOMKINS G, BALDEN E, SANTOO J, KROENKE K: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. I Med. (2000) 108:65-72. ••A review and meta-analysis ofantidepressants for IBS.
   Google Scholar
• CAMILLERI M: Ten secrets for development of drugs for functional gastrointestinal diseases. Gastroenterology (2000) 118:653.
   PubMed Web of Science ®Google Scholar
• PRIOR A, READ NW: Reduction of rectal sensitivity and post-prandial motility by granisetron, 5-HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol Ther. (1993) 7:175–180.
   PubMed Web of Science ®Google Scholar
• ZIGHELBOIM J, TALLEY NJ, PHILLIPSJF etal.: Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin Type 3 antagonism. Dig. Dis. Sri. (1995) 40:819–827.
   Google Scholar
• KOZLOWSKI CM, GREEN A, GRUNDY D etal.: The 5-HT3 receptor antagonist alosetron inhibits the colorectal distension induced depressor response and spinal c-fos expression in the anesthetised rat. Gut (2000) 46:474–480.
   Google Scholar
• DELVAUX M, LOUVEL D, MAMET JP et al: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol Ther. (1998) 12:849–855.
   PubMed Web of Science ®Google Scholar
• HAMMER J, PHILLIPS SF, TALLEY NJ etal: Effects of a 5-HT3 receptor antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment. Pharmacol Ther. (1993) 7:543–551.
   PubMed Web of Science ®Google Scholar
• GOLDBERG PA, KAMM MA, SETTI-CARRARO P et al: Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion (1996) 57:478–483.
   PubMed Web of Science ®Google Scholar
• MAXTON DG, MORRIS J, WHORWELL PJ: Selective 5-hydroxy-tryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment. Pharmacol Ther. (1996) 10:595–599.
   Google Scholar
• STEADMAN CJ, TALLEY NJ, PHILLIPS SF, ZINSMEISTER AR: Selective 5-hydroxytryptamine Type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant irritable bowel syndrome - a pilot study. Mayo Chu. Proc. (1992) 67:732–738.
   PubMed Web of Science ®Google Scholar
• CAMILLERI M, MAYER EA, DROSSMAN DA et al: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol Ther. (1999) 13:1149-1159. •Alosetron improves bowel function and pain sensation in female IBS patients.
   Google Scholar
• BARDHAN KD, BODEMAR G, GELDOF H et al: A double-blind, randomised, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol Ther. (2000) 14:23–34.
   PubMed Web of Science ®Google Scholar
• VIRAMONTES B, MCKINZIE S, PARDI DS etal.: Alosetron retards small bowel and overall colonic transit in diarrhoea-predominant irritable bowel syndrome (D- IBS). Gastroenterology (2000) 118:A848.
   Google Scholar
• CAMILLERI M, NORTHCUTT AR, KONG S et al: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 355:1035-1040. •A RCT of alosetron.
   Google Scholar
• JONES RH, HOTMANN G, RODRIGO L et al: Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment. Pharmacol. Ther. (1999) 13:1419–1427.
   PubMed Web of Science ®Google Scholar
• FRIEDEL D, THOMAS R, FISHER RS: Ischemic colitis during treatment with alosetron. Gastroenterology (2001) 120:557–560.
   PubMed Web of Science ®Google Scholar
• WILDE MI, MARKHAM A: Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs (1996) 52:773–794.
   Google Scholar
• BHARUCHA AE, CAMILLERI M, FERBER I et al: Effects of serotonin (5-HT4) receptor antagonist on gastrointestinal (GI) transit, colonic motor and sensory function in health. Gastroenterology (1999) 116:G4170. Abstract.
   Google Scholar
• SANGER GJ, BANNER SE, SMITH MI etal: SB-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models. Neurogastroenterol Moth. (1998) 10:271–279.
   Google Scholar
• SANGER GJ, YOSHIDA M, YAHYAH M et al: Increased defecation during stress or after 5-hydroxytryptophan: selective inhibition by the 5-HT4 receptor antagonist, SB-207266. Br. J. Pharamcol. (2000) 130:706–712.
   Web of Science ®Google Scholar
• HOUGHTON LA, JACKSON NA, WHORWELL PJ et al: 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit. Aliment. Pharmacol Ther. (1999) 13:1437–1444.
   PubMed Web of Science ®Google Scholar
• SMITH MI, BANNER SE, SANGER GJ: 5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats. Neurosci. Lett. (1999) 271:61–64.
   Google Scholar
• SCOTT LJ, PERRY CM: Tegaserod. Drugs (1999) 58(3):497–498.
   Google Scholar
• GRIDER JR, FOXX-ORENSTEIN AE, JIN JG: 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology (1998) 115:370–380.
   PubMed Web of Science ®Google Scholar
• NGUYEN A, CAMILLERI M, KOST LJ et al: SDZ HTF 919 stimulates colonic motility and transit In viva j Pharmacol Exp. Ther. (1997) 280:1270–1276.
   Google Scholar
• COELHO AM, ROVIRA P, FIORAMONTI J et al: Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology (2000) 118:A834.
   Google Scholar
• SCHIKOWSKI A, MATHIS C, THEWISSEN M et al: Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist. Gastroenterology (1999) 117:A643.
   Google Scholar
• PRATHER CM, CAMILLERI M, ZINSMEISTER AR et al: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 118:463–468.
   PubMed Web of Science ®Google Scholar
• APPEL S, KUMLE A, MEIER R: Clinicalpharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Gastroeriterolog y (1999) 116 A1066.
   Google Scholar
• VON DER OHE MR, KLINGENBURG S, GOEBELL H et al: In vivo modulation of left colonic motor function in healthy humans: role of the 5-HT4 receptor. Digestion (1998) 59:A856.
   Google Scholar
• HAMLING J, BANG CJ, TARPILA S et al: Titration regimen indicates partial 5-HT4 receptor agonist (HFT 919) improves symptoms in constipation predominant irritable bowel syndrome (C-IBS). Digestion (1998) 59(53):735.
   Google Scholar
• LEFKOWITZ MP, RUEGG P, SHI Y et al: Relief of overall symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF919. Gastroenterology (1999) 116:A1027.
   Web of Science ®Google Scholar
• MUELLER-LISSNER S, FUMAGALLI I, BARDHAN KD et al: Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome. Gastroenterology (2000) 118:A175.
   Google Scholar
• LANGAKER KJ, MORRIS D, PRUITT R etal.: The partial 5-HT4 (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome. Digestion (1998) 59(53):20.
   Google Scholar
• DRICI MD, EBERT SN, WANG WX et al: Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. Cardiovasc. Pharinacol (1999) 34:82–88.
   PubMedGoogle Scholar
• APPEL S, KUMLE A, HUBERT M et al: First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. Pharinacol (1997) 37:229–237.
   PubMed Web of Science ®Google Scholar
• CAMILLERI M: Review article: tegaserod. Aliment. Pharinacol. Ther. (2001) 15:277-289. •A complete review of tegaserod.
   Google Scholar
• WHORWELL PJ, KRUMHOLZ S, MULLER-LISSNER S et al: Tegaserod has a favorable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome. Gastroenterology (2000) 118:A1204.
   Google Scholar
• BRIEJER MR, BOSMANS JP, VAN DAELE P et al: The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. Ph= (2001) 423:71–83.
   PubMed Web of Science ®Google Scholar
• PRINS NH, VAN HASELEN JF, LEFEBVRE RA et al.: Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br Pharinacol. (1999) 127:1431–1437.
   Google Scholar
• BRIEJER MR, GHOOS E, EELEN J et al:Serotonin 5-HT4 receptors mediate the R093877- induced changes in contractile patterns in the canine colon. Gastroenterology (1997) 112:A705.
   Google Scholar
• POEN AC, FELT-BERSMA RJF, VAN DONGEN PAM et al: Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment. Pharmacol. Ther. (1999) 13:1493–1497.
   PubMed Web of Science ®Google Scholar
• EMMANUEL AV, KAMM MA, ROY AJ et al.: Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut (1998) 42:511–516.
   PubMed Web of Science ®Google Scholar
• BOURAS EP, CAMILLERI M, BURTON DD et al.: Selective stimulation of colonic transit by the benzofuran 5-HT4 agonist, prucalopride, in healthy humans. Gut (1999) 44:682–686.
   PubMed Web of Science ®Google Scholar
• BOURAS EP, CAMILLERI M, BURTON DD et al.: Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology (2001) 120:354–360.
   PubMed Web of Science ®Google Scholar
• JOHANSON JF, MINER PB, PARKMAN HP et al.: Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: results of two double-blind, placebo-controlled trials. Gastroenterology (2000) 118:A175.
   Web of Science ®Google Scholar
• MINER PB, NICHOLS T, SILVERS DR et al.: The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology (1999) 116:A1043.
   PubMed Web of Science ®Google Scholar
• OTTEN M, SCHNEIDER H, WURZER H et al: A double-blind, placebo controlled evaluation of safety and efficacy of 12-week, twice-daily treatment with prucalopride in patients with chronic constipation. Gastroenterology (1999) 116:A1055.
   Web of Science ®Google Scholar
• RUTH M, HAMELIN B, ROHSS K et al: The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol Ther. (1998) 12:35–40.
   PubMed Web of Science ®Google Scholar
• COULIE B, TACK J, JANSSEN J: Influence of buspirone-induced fundus relaxation on the perception of gastric distension in man. Gastroenterology (1997) 112:A715.
   Google Scholar
• TACK J, PIESSEVAUX H, COULIE B et al.: A placebo-controlled trial of buspirone, a fundus-relaxing drug, in functional dyspepsia: effect on symptoms and gastric sensory and motor function. Gastroenterology (1999) 116:A325.
   Google Scholar
• COULIE B, TACK J, MAES B et al.: Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am. Physiol (1997) 272:G902–G908.
   Google Scholar
• HOUGHTON LA, FOWLER P, KEENE ON et al.: Effect of sumatriptan, a new selective 5-HT1-like agonist, on liquid gastric emptying in man. Aliment. Pharmacol Ther. (1992) 6:685–691.
   PubMedGoogle Scholar
• TACK J, COULIE B, WILMER A et al.: Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut (2000) 46:468–473.
   PubMed Web of Science ®Google Scholar
• TACK J, PIESSEVAUX H, COULIE B et al.: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology (1997) 112:A715.
   Google Scholar
• DE PONTI E CREMA E NARDELLI G et al.: Blockade by the selective 5-HT1Be receptor antagonist GR 127935 of the effect of sumatriptan on canine gastric compliance. Neurogastroenterol Moth. (2000) 12:383.
   Google Scholar
• CORAZZIARI E: Role of opioid ligands in the irritable bowel syndrome. Can. j Gastroenterol (1999) 13:71A–75A.
   Google Scholar
• SHANNON S, HOLLINGS WORTH J, COOK IJ et al.: Effect of trimebutine on postprandial colonic motor activity in healthy subjects and patients with irritable bowel syndrome. j Gastroenterol Mod]. (1989) 1:9–14.
   Google Scholar
• DELVAUX M, WINGATE D: Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. j Int. Med. Res. (1997) 25:225–246.
   PubMed Web of Science ®Google Scholar
• DIOP L, RIVIERE P, PASCAUD X et al.: Peripheral kappa opioid receptors mediate the antinociceptive effect of fedotozine on the duodenal pain reflex in rat. Eur. Pharmacol (1994) 271:65–71.
   PubMedGoogle Scholar
• PASCAUD N, HONDE C, LE GALLOU B: Effects of fedotozine on gastrointestinal motility in dogs: mechanism of action and related pharmacokinetics. j Pharm. Pharmacol (1990) 42:546–552.
   PubMed Web of Science ®Google Scholar
• JUNIEN JL, RIVIERE P: The hypersensitive gut-peripheral kappa agonists as a new pharmacological approach. Ailment. Pharmacol Ther. (1995) 9:117–126.
   PubMed Web of Science ®Google Scholar
• LANGLOIS A, DIOP L, FRIESE N et al: Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors. Eur. j Pharmacol (1997) 324:211–217.
   PubMed Web of Science ®Google Scholar
• RIVIERE P, PASCAUD X, CHEVALIER E et al.: Fedotozine reversal of peritoneal-irritation-induced ileus in rats: possible peripheral action on sensory afferents. Pharmacol Exp. Ther. (1994) 270:846–850
   PubMedGoogle Scholar
• COFFIN B, BOUHASSIRA D, CHOLLET R et al.: Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Ailment. Pharmacol Ther. (1996) 10:919–925.
   PubMed Web of Science ®Google Scholar
• DAPOIGNY M, ABITBOL JL, FRAITAG B: Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig. Dis. Sci. (1995) 40:2244–2248.
   PubMed Web of Science ®Google Scholar
• DELVAUX M, LOUVEL D, LAGIER E et al.: The lc agonist fedotozine relieves hypersensitivity to colonic distension in patients with irritable bowel syndrome. Gastroenterology (1999) 116:38–45.
   PubMed Web of Science ®Google Scholar
• DAPOIGNY M, ABITBOL JL, MERIC G, GENEVE J, FRAITAG B: Fedotozine in irritable bowel syndrome: results of a 6 week placebo-controlled multicenter therapeutic trial. Gastroenterology (1995) 108:A588.
   Web of Science ®Google Scholar
• ABITOL JL, SCHERRER B, DE MEYNARD C et al.: Efficacy of fedotozine in functional dyspepsia: a meta-analysis of individual data from randomised, placebo-controlled studies. Cut (1996) 39:A229–A230.
   Google Scholar
• FRAITAG B, HOMERIN M, HECKETSWEILER P: Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig. Dis. Sci. (1994) 39:1072–1077.
   PubMed Web of Science ®Google Scholar
• READ NW ABITOL JL, BARDHAN KD et al.: Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Cut (1997) 41: 664–668.
   Google Scholar
• DELVAUX M: Pharmacology and clinical experience with fedotozine. Expert Opin. Investig. Dugs. (2001) 10:97-110. •Fedotozine review.
   Google Scholar
• FEINLE C, METER 0, OTTO B et al.: Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Cut (2001) 48:347–355.
   Google Scholar
• CANN PA, ROVATI LC, SMART HL et al.: Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multi-center clinical study. Ann. N Y Acad. Sci. (1994) 713:449–450.
   PubMed Web of Science ®Google Scholar
• FARTHING MJ: New drugs in the management of the irritable bowel syndrome. Drugs (1998) 56:11–21.
   PubMedGoogle Scholar
• BRADETTE M, DELVAUX M, STAUMONT G etal.: Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig. Dis. Sci. (1994) 39:1171–1178.
   Google Scholar
• HASLER WL, SOUDAH HC, OWYANG C: Somatostatin analog inhibits afferent response to rectal distension in diarrhoea-predominant irritable bowel patients. Pharmacol. Exp. Ther. (1994) 268:1206–1211.
   PubMed Web of Science ®Google Scholar
• BHARUCHA AE, CAMILLERI M, ZINMEISTER AR: Adrenergic modulation of human colonic motor and sensory function. Am. j Physiol. (1997) 273:G997–1006.
   PubMed Web of Science ®Google Scholar
• MALCOLM A, PHILLIPS SF, CAMILLERI M etal.: Pharmacological modulation of rectal tone alters perception of distension in humans. Am. Castroenterof (1997) 92:2073–2079.
   Google Scholar
• PRIOR A, WILSON KM, WHORWELL PJ: Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (1988) 2:535–539.
   PubMedGoogle Scholar
• AWAD RA, LLORENS E CAMELO AL et al.: A randomised double-blind placebo-controlled trial of lidamidine HCL in irritable bowel syndrome. Acta. Gastroent. Latinoamer. (2000) 30:169–175.
   Google Scholar
• MERTZ HR: New concepts of irritable bowel syndrome. Cur. Castro. Rep. (1999) 1:433–440.
   Google Scholar
• KAMM MA, FARTHING MJG, LENNARD-JONES JE: Bowel function and transit rate during the menstrual cycle. Gut (1989) 30:605–608.
   PubMed Web of Science ®Google Scholar
• MATHIAS JR, CLENCH MH, REEVES-DARBY VG et al.: Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Dig. Dis. Sci. (1994) 39:1155–1162.
   PubMed Web of Science ®Google Scholar
• MATHIAS JR, CLENCH MH, ROBERTS PH et al.: Effect of leuprolide acetate in patients with functional bowel disease: long-term follow-up after double-blind, placebo-controlled study. Dig. Dis. Sci. (1994):1164–1170.
   Google Scholar
• MATHIAS JR, CLENCH MH, ABELL TL etal.: Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease. Dig. Dis. Sci. (1998) 43:1347–1355.
   Google Scholar